RVMD · Revolution Medicines, Inc.
$183.90
-1.65% last session
End-of-day data · close of 2026-10-26
Market cap
$39B
Enterprise value
$37B
Trailing P/E
—
Forward P/E
-31.9
Dividend yield
0.0%
Beta
1.40
Avg volume
2M
Employees
1K
Daily Change %
-1.65%
5 Days Change
-2.02%
10 Days Change
3.34%
30 Days Change
-10.28%
60 Days Change
-11.54%
Month to Day Change
-10.68%
Year to Day Change
130.89%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RVMD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
RBC Capital
Outperform$260
+41.4% vs priceBank of America
Buy$265
+44.1% vs priceMorgan Stanley
Overweight$255
+38.7% vs priceUBS
Buy$265
+44.1% vs priceWells Fargo
Overweight$167
-9.2% vs priceJP Morgan
Overweight$122
-33.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Reiterates | Buy | $0.00 → $250 |
| 2026-10-19 | Truist Securities | Maintains | Buy | $240 → $241 |
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-15 | Needham | Reiterates | Buy | $275 |
| 2026-10-14 | RBC Capital | Maintains | Outperform | $259 → $260 |
| 2026-10-08 | RBC Capital | Maintains | Outperform | $251 → $259 |
| 2026-10-07 | Truist Securities | Maintains | Buy | $239 → $240 |
| 2026-09-28 | Brookline Capital | Initiates | Buy | $0.00 → $318 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 8.6% below the 50-day MA ($201.18).
- bullish: Price vs 200-day MA: Trading 18.9% above the 200-day MA ($154.64).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.50) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($54.48) and high ($221.15).
RVMD Price Chart
Loading chart for RVMD…
Fundamentals
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
GMAB
Genmab A/S
$27B 45.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.